Effects of Hyperuricemia on Renal Function of Renal Transplant Recipients: A Systematic Review and Meta-Analysis of Cohort Studies

Yan Huang1, Yu-Lin Li2, He Huang3, Ling Wang4, Wen-Ming Yuan5, Jing Li1, *  

1 Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China, 2 The Second Clinical Medical College of Chengdu University of TCM, Chengdu University of TCM, Chengdu, People’s Republic of China, 3 Department of Cardiology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China, 4 Department of Cardiology, The People’s Hospital of Mianyang, Mianyang, People’s Republic of China, 5 Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, People’s Republic of China

Abstract

Background: Hyperuricemia is an independent risk factor of nephropathy, but its role in renal transplant recipients (RTRs) is controversial.

Methods: Based on the methods of Cochrane systematic reviews, we searched MEDLINE (1948–2011.6), EMBASE (1956–2011.6), CBM (Chinese Biomedicine Database) (1978–2011.6) to identify cohort studies assessing the association between uric acid level and kidney allograft. Two authors independently screened the studies, assessed the risk of bias of included studies and extracted data. Unadjusted odds ratio (OR), mean difference (MD), adjusted hazard ratio (aHR) and their corresponding 95%CI were pooled to assess the effects of hyperuricemia on kidney allograft.

Results: Twelve cohort studies were included and the quality was moderate to high based on the NEWCASTLE-OTTAWA quality assessment scale. RTRs with hyperuricemia had lower eGFR (P<0.0001, 95%CI—16.34—6.14) and higher Scr (P<0.00001, 95%CI 0.17—0.31) than those with normal uric acid level. Meta-analysis showed that hyperuricemia was a risk factor of chronic allograft nephropathy (Unadjusted OR = 2.85, 95%CI 1.84—4.38, adjusted HR = 1.65, 95%CI 1.02—2.65) and graft loss (Unadjusted OR = 2.29, 95%CI 1.55—3.39; adjusted HR = 2.01, 95%CI 1.39—2.94).

Conclusions: Current evidence suggests that hyperuricemia may be an independent risk factor of allograft dysfunction. Hyperuricemia may modestly increase the risk of poor outcomes of RTRs. Future research is needed to verify whether lowering uric acid level could improve the kidney function and prognosis of RTRs with hyperuricemia.

Introduction

Kidney transplantation has become a routine procedure in patients with end-stage renal failure as the development of kidney transplant technique and medicine. However, shortage of donors, the long-term outcomes and morbidity of kidney transplant patients are still remained problems [1]. Multiple factors contribute to long-term function and survival of the allograft. One study has shown that all kidney transplant recipients (RTRs) inevitably have or will have chronic kidney disease (CKD) as a result of the development of chronic allograft nephropathy (CAN) [2].

Increasing experimental and epidemiological studies suggest that hyperuricemia may play a role in the progression of cardiovascular and renal diseases. UA induces endothelial cell dysfunction, decreases nitric oxide production [3,4,5], stimulates vascular smooth muscle cell proliferation [6,7], activates renin-angiotensin system [8] and produces various inflammatory mediators [9,10]. Studies have found an independent association between hyperuricemia and hypertension, coronary heart disease, ischemic stroke, chronic renal diseases and type 2 diabetes [11]. Hyperuricemia is common among kidney transplant recipients, especially those on cyclosporine-based immunosuppressive regimens [12]. The incidence of hyperuricemia in kidney transplant patients, which was ~25% before the routine use of cyclosporine, has increased to >80% with the widespread use of cyclosporine [12]. Increased UA level has been shown to be predictive of incident kidney disease and end-stage renal disease in those with normal renal function and progression of disease in individuals with kidney disease [13], while reduction of serum UA with allopurinol has been associated with slowing of the progression of renal disease [14]. Therefore, it has been proposed that hyperuricemia may have clinical significance in RTRs, but studies show conflicting results of the role of hyperuricemia in renal allograft recipients. We conducted a systematic review and meta-analysis of cohort studies to assess the association between serum UA levels and graft function and survival after kidney transplan-
tation in an effort to clarify whether early-onset hyperuricemia is an independent predictor of long-term graft outcomes.

**Methods**

**Searching**

A comprehensive literature search was performed using databases MEDLINE (Ovid) from 1948 until June 2011, Medline (R) in-process & other no-indexed citations (2011.5), EMBASE from 1956 until June 2011 and CBM (Chinese Biomedicine Database) from 1978 until June 2011. The Medical Subject Heading (MeSH) ‘urate’, ‘uric acid’, ‘hyperuric’, ‘hyperuricemia’, ‘gout’, ‘transplant’, ‘transplantation’ and ‘graft’ were used as English and corresponding Chinese search terms to identify studies from above database. The search strategies were adjusted based on the characteristics of each database. In addition, we searched the reference lists of all identified relevant studies.

**Selection**

We only included prospective or retrospective cohort studies investigating the association of hyperuricemia with RTRs’ kidney function and long-term outcomes. Eligible studies must meet following criteria: patients with age older than 18, maintained intact renal function more than 6 months to minimize the effects of decreased graft function on hyperuricemia, and only one kidney transplanted. Patients were excluded if they had a history of malignant tumor, acute inflammation, acute renal allograft rejection and active liver disease.

Studies on drug trials, not published in English or Chinese, letters and review articles, and studies without available data were excluded.

**Validity Assessment**

Two reviewers rated the quality of the eligible studies independently. Study quality was judged by using the NEWCASTLE-OTTAWA quality assessment scale. We assessed included studies based on three aspects: the selection of the study groups (0–4 points), the comparability of the groups (0–2 points), and the ascertainment of either the exposure or outcome of interest (0–3 points). The total score was 9. In case of disagreement, consensus was achieved by discussion with a third adjudicator.

**Data Abstraction**

Data were extracted by two reviewers independently. For each study, we extracted information on author, publication year, country, study design, sample size, age and sex of RTRs, the definition of hyperuricemia, the length of follow-up and adjusted factors. Estimated glomerular filtration rate (eGFR) and serum creatinine (Scr) were as primary end-point, and CAN diagnosed by biopsy and graft loss during follow-up were as secondary end-point.

**Quantitative Data Synthesis**

Extracted information was put into a table to help us browse the sample size, research design, quality and key features of each included study.

RevMan5.0 was used to pool unadjusted odds ratio (OR) of dichotomous variable, mean difference (MD) of continuous variable and obtain their corresponding 95% CI while STATA10 was used to pool adjusted hazard ratio (aHR) and obtain 95% CI. Chi-square test was used to assess the heterogeneity of included studies. We adopted a p-value of ≤0.1 as evidence of heterogeneity. The random effects model was used to pool data if there was heterogeneity, otherwise fixed effect model. A two-sided p value less than 0.05 was regarded as significant for all analyses. Subgroup analysis was performed to pool the effect size of prospective and retrospective cohort studies separately. Sensitivity analysis was performed by removing studies with distinctive definition of hyperuricemia. Meta-regression was performed to assess the effect of several clinical factors and study design on outcomes.

**Results**

**Flow of Included Studies**

The primary search strategy identified 1417 articles. After scanning the titles and abstracts, 1397 articles were excluded (reasons stated in Figure 1). After reading the full text of remaining studies and references tracing, 12 studies [15,16,17,18,19,20,21,22,23,24,25,26] which met the inclusion criteria were included in the review (Figure 1).

**Study Characteristics and Quality**

Table 1 summarized the characteristics of the included studies. Among these studies, six were prospective and six were retrospective cohort studies. The sample size ranged from 45 to 488. The studies were undertaken in U.S, China, Korea, Poland, German, Canadian, Turkey and Saudi Arabia. Eight studies [15,17,19,21,22,23,24,25] with 2045 participants assessed the effects of UA on eGFR of RTRs; Five studies [18,20,21,22,23] with 873 participants assessed the effects of UA on Scr of RTRs; Five studies [19,20,21,22,24] with 1178 participants assessed the effects of UA on CAN and 5 studies [15,16,22,24,26] with 1519 participants assessed the effects of UA on graft loss (including death with functional graft). Follow-up time ranged from 1 to 10 years. All studies controlled the factors which had effects on graft outcomes.
Table 1. The character of included study and score of quality assessment.

| study          | country | study design | sample size(H/N) | Age (H/N) | definition of hyperuricemia | Time of evaluating eGFR since transplant (month) | follow-up | comparable of baselines | adjusted factors                                                                 | score of quality assessment |
|----------------|---------|--------------|------------------|-----------|-------------------------------|-----------------------------------------------|-----------|----------------------------|----------------------------------------------------------------------------------|----------------------------|
| Haririan 2011  | U.S     | Co,R         | 488              | 52.6±13.1 | NS                            | 12                                            | 41.1±17.7 | Y                         | eGFR, race, donor, peak-PRA, HLA-mismatch, delayed graft function, acute cellular rejection, MMF dose, ACEI/ARB | 8                          |
| Chung 2010     | Korea   | Co,P         | 148/208          | H: 38.4±10.4 N: 39±10.50 | > 7.0 mg/dl for man; > 6.0 mg/dl for woman | 12                                            | N: 105.68±31.9 months; H: 100.78±33.8 | Y                         | age, sex, postoperative recovery pattern, the presence of diabetes or hypertension, BMI, retransplantation, donor type, HLA mismatch number, immunosuppressant type, and acute rejection episodes, TA-eGFR | 9                          |
| Zou 2010       | China   | Co,R         | 58/84            | NS        | > 420 umol/l for man and > 380 umol/l for woman | 12                                            | 34 for 1 year; 42 for 2 years; 140 for 3 years | NS                       | unadjusted                                                                       | 7                          |
| Haririan 2010  | U.S     | Co,R         | 45/167           | H: 50.5±12.9 N: 47.2±13.9 | > 7.0 mg/dl for man and > 6.5 mg/dl for woman | 12                                            | 68.3±27.2 | Y                         | age, retransplantation, diabetes and induction                                   | 8                          |
| Karbowska 2009 | Poland  | Co,R         | 48/30            | 47.8/45.3 | NS                            | NS                                            | H: 30.5 months; N: 32.0 months | Y                         | unadjusted                                                                       | 8                          |
| Akalin 2008    | Canada  | Co,P         | 144/163          | H: 50.0±1.0 N: 47.7±1.0 | > 7.0 mg/dl for man and > 6.5 mg/dl for woman | 6                                             | mean 4.3 years | Y                      | age, race, sex, eGFR, having received a cadaveric transplant, and ciclosporin use. | 8                          |
| Bandukwala 2009| Canada  | Co,R         | 180/225          | H: 50.2±11 N: 50.3±12 | > 7.1 mg/dl for man and > 6.1 mg/dl for woman | NS                                            | N: 6.0±6 years; H: 7.3±6 years | Y                         | unadjusted                                                                       | 8                          |
| Kim 2010       | Korea   | Co,R         | 55/301           | H: 36.8±10.8 N: 39.7±10.3 | > 7.0 mg/dl for man and > 6.0 mg/dl for woman | 6                                             | 102.63±27.25 | Y                    | unadjusted                                                                       | 8                          |
| Min 2009       | Korea   | Co,P         | 24/97            | H: 41.2±12.3 N: 39.8±12.2 | > 8.0 mg/dl for both man and woman | 12                                            | −5 years | Y                         | unadjusted                                                                       | 8                          |
| Gerhöardt U1999| German  | Co,P         | 80/268           | 41.1±12.78 | > 8.1 mg/dl for man and > 6.1 mg/dl for woman | NS                                            | 5years | Y                         | unadjusted                                                                       | 9                          |
| Akgu 2007      | Turkey  | Co,P         | 54/79            | 34.7±9.9 | > 7.0 mg/dl for man and > 6.0 mg/dl for woman | NS                                            | 3 years | NS                       | unadjusted                                                                       | 8                          |
| Abdelrahman 2002| Saudi   | Co,P         | 25/20            | NS        | > 8.0 mg/dl for man and > 6.0 mg/dl for woman | NS                                            | 8.9±4.6 years | Y          | unadjusted                                                                       | 7                          |

NS: not stated; N: normal uric acid group; H: hyperuricemia group; eGFR: estimated glomerular filtration rate; SCr: serum creatinine; Co: cohort study; R: retrospective; P: prospective; PRA: pane-reactive antibody. doi:10.1371/journal.pone.0039457.t001
kidney function more or less, including age, race, sex, diabetes, tumor, and medicines.

We assessed the quality of included studies critically using NEWCASTLE – OTTAWA quality assessment scale. Two studies [16,20] scored 9; two studies [17,18] scored 7; the rest scored 8 (table1). The subjects of all included studies were patients with intact renal function for half a year after transplantation. Patients with hyperuricemia or normal serum uric acid level were comparable in baselines except 2 studies [17,18] which did not report the relevant information. All studies except two [23,26] described the definition of hyperuricemia. The follow-up of each study was more than 1 year and the drop-out was described.

Hyperuricemia with eGFR

A total of 8 studies [15,17,19,21,22,24,25] provided data on eGFR of RTRs with hyperuricemia versus normouricemia. There was significant heterogeneity among studies ($I^2 = 95\%$, $p < 0.00001$). Random-effects meta-analysis showed that RTRs with hyperuricemia had significantly lower eGFR than those with normal serum uric acid level ($MD = -11.24$, 95% CI $-16.34$ to $-6.14$) (Figure 2).

We performed a subgroup analysis by pooling prospective and retrospective studies separately and the results showed that there were significant heterogeneity among both prospective cohort studies ($I^2 = 93\%$, $p = 0.0001$) and retrospective cohort studies ($I^2 = 85\%$, $p < 0.00001$). Random-effects meta-analysis showed that RTRs with hyperuricemia in both prospective and retrospective studies had significantly lower eGFR than those with normal serum uric acid level although the effect size of prospective cohort studies ($MD = -14.86$, 95% CI $-22.10$ to $-7.63$) was larger than that of retrospective cohort studies ($MD = -9.99$, 95% CI $-15.00$ to $-4.98$) (Figure 2).

Sensitivity analysis was performed by removing 3 studies [22,23,24] with distinctive definition of hyperuricemia, there was significant heterogeneity among studies ($I^2 = 93\%$, $p < 0.00001$). Random-effects meta-analysis still showed that RTRs with hyperuricemia had significantly lower eGFR than those with normal serum uric acid level ($MD = -13.48$, 95% CI $-19.15$ to $-7.81$).

A random model meta-regression analysis was performed using the indicators of follow-up, race, definition of hyperuricemia, study type ($P = 0.0016$). This led to a relative decrease in heterogeneity ($R^2 = 100\%$) with the residual of 0.00%. Meta-regression analysis disclosed significant interactions between race ($\beta = -8.492514$, $P = 0.002$), study type ($\beta = 5.035018$, $P = 0.013$), definition of hyperuricemia ($\beta = 10.0255$, $P = 0.006$), and follow-up ($\beta = 13.37142$, $P = 0.002$).

Hyperuricemia with SCr

We pooled the data of SCr of RTRs with hyperuricemia versus normouricemia in 5 studies [18,20,21,22,23]. There was no heterogeneity among these studies ($I^2 = 44\%$, $P = 0.13$). Fixed-effect model meta-analysis showed that RTRs with hyperuricemia had significantly higher SCr than those with normal serum uric acid level ($MD = 0.24$, 95% CI $0.17$ to $0.31$) (Figure 3).
Hyperuricemia with CAN

The number of patients who developed CAN during the follow-up was available in 4 studies [19,20,21,22]. There was no statistical significant heterogeneity among these studies ($I^2 = 26\%, p = 0.26$). Fixed-effect model meta-analysis showed that RTRs with hyperuricemia had significantly higher risk of developing CAN than those with normal serum uric acid level (unadjusted OR = 2.85, 95% CI 1.85–4.38) (Figure 4).

Two studies [19,24] reported the adjusted hazard ratio (aHR) of hyperuricemia with CAN of RTRs. There was no heterogeneity among the studies ($I^2 = 0.0\%, p = 0.444$). Fixed-effect model meta-analysis showed that hyperuricemia was an independent risk factor of CAN of RTRs (aHR = 1.65, 95% CI 1.02–2.65) (Table 2).

Hyperuricemia with Graft Loss

Three studies [15,16,22] reported the number of patients who suffered from graft loss. There was no heterogeneity among the studies ($I^2 = 0.0\%, p = 0.79$). Fixed-effect model meta-analysis showed that RTRs with hyperuricemia had significantly higher risk of graft loss than those with normal serum uric acid level (unadjusted OR = 2.29, 95% CI 1.55–3.39) (Figure 5).

Three studies [15,22,24] reported the aHR of hyperuricemia with graft loss of RTRs. There was no heterogeneity among the studies ($I^2 = 0.0\%, p = 0.949$). Fixed-effect model meta-analysis showed that hyperuricemia was an independent risk factor of graft loss of RTRs (aHR = 2.01, 95% CI 1.39–2.94) (Table 2).

Three studies [15,22,26] reported the aHR of increase 1 mg/dl uric acid with graft loss of RTRs. There was no heterogeneity among the studies ($I^2 = 0.0\%, p = 0.649$). Fixed-effect model meta-analysis showed that uric acid was positively associated with graft loss of RTRs independently (aHR = 1.21, 95%CI 1.08–1.37) (Table 2).

Discussion

Relationship of Hyperuricemia with Kidney Function of RTRs

Studies reported that UA may induce graft dysfunction, chronic allograft nephropathy and accelerate the progress of the chronic kidney disease through triggering inflammation, affecting vascular endothelial function and inducing microvascular injury. Intracellular uric acid could trigger oxidative stress reaction; activate inflammatory mediators such as interleukin-6, tumor necrosis factor-α, C-reactive protein [3,4,9,10] and renin-angiotensin systems that finally lead to vascular endothelial dysfunction and microvascular injury [27,28].

Our review found that eGFR in the hyperuricemia group was significantly lower than that in normouricemia group while the Scr level in the hyperuricemia group was significantly higher than that in normouricemia group. Both unadjusted and adjusted pooled effect size showed that the incidence rate of CAN and graft loss in hyperuricemia group was significantly higher than that in the normouricemia group, implying that hyperuricemia may be an independent risk factor of graft dysfunction and could modestly increase the risk of poor outcomes of kidney transplant receptors.

Table 2. Adjusted hazard ratio of hyperuricemia with graft loss, chronic allograft nephropathy (CAN).

| Outcome                        | included study | Variable type | aHR (95%CI) | heterogeneity I², P-value | meta analysis aHR (95%CI) |
|--------------------------------|----------------|---------------|-------------|---------------------------|----------------------------|
| hyperuricemia with graft loss  | Min 2009       | DV            | 2.01(1.09–3.72) | 0.00%, 0.949             | 2.01 (1.39–2.94)          |
|                                | Haririan2010   | DV            | 1.92(1.1–3.4)  |                           |                            |
|                                | Chung2010      | DV            | 2.3(0.9–5.8)   |                           |                            |
| hyperuricemia with CAN         | Akalin2008     | DV            | 1.28(0.57–2.64) | 0.00%, 0.444             | 1.65 (1.02–2.65)          |
|                                | Min 2009       | DV            | 1.89(1.05–3.43) |                           |                            |
| 1 mg/dl increase of UA with graft loss | Haririan2010 | CV            | 1.26(1.03–1.53) | 0.00%, 0.649             | 1.21 (1.08–1.37)          |
|                                | Haririan2011   | CV            | 1.14(0.95–1.36) |                           |                            |
|                                | Chung2010      | CV            | 1.3(1.0–1.7)    |                           |                            |

DV: dichotomous variable; CV: continuous variable; aHR: adjusted hazard ratio.
Hyperuricemia with Kidney Transplantation

Clinical trials about the effects of urate-lowering therapy on kidney transplant recipients can provide direct evidence that higher uric acid is an independent risk factor of poor prognosis of renal transplant patients. RCT performed by Goicoechea et al suggested that urate-lowering therapy slowed down renal disease progression of patients with chronic kidney disease (In the control group, eGFR decreased 3.3 ± 1.2 ml/min per 1.73 m\(^2\), and in the allopurinol group, eGFR increased 1.3 ± 1.3 ml/min per 1.73 m\(^2\) after 24 months) [29]. However, there are only 2 trials [30,31] reported the effects of urate-lowering therapy on kidney transplant patients. Navascues et al reported that it is safe to use allopurinol to low hyperuricemia of kidney transplant recipients, but the SCr didn’t change significantly after treatment (2.35 ± 0.92 mg/dl vs. 2.39 ± 0.13 mg/dl) [31]. Flury et al compared the effects of allopurinol vs. benz bromarone in the treatment of hyperuricemia after kidney transplantation, both drugs effectively lowered serum uric acid concentrations by 19% vs. 35% of pretreatment values [30]. Unfortunately, there is no evidence to suggest that the allograft function of patients with urate-lowering therapy is better than that of kidney transplant recipients without urate-lowering drug. Therefore, high quality evidence is needed to show that decreased uric acid level is related to good prognosis of kidney transplant recipients.

Hyperuricemia and Graft Dysfunction, Cause or Effects?

Kidney is an important metabolic pathway of uric acid. When kidney function is compromised, the excretion of uric acid decreases while the level of serum uric acid increases. One study reported that renal dysfunction is associated with higher UA levels, but higher UA levels is not parallel with the progression of renal dysfunction independently after kidney transplantation [32]. Min et al found that recipients in the early-onset hyperuricemia (within 1 year after transplantation) had a stable graft function. The eGFR are 58.7±10.8, 58.9±11.5 and 58.8±10.7 ml/min/1.73 m\(^2\), respectively at detection of hyperuricemia, at 6 months post-transplantation, and at 12 months post-detection [24]. Chung et al found that UA-level of RTRs increased from 5.3±1.9 mg/dl to 6.3±1.7 mg/dl within 3 months post-transplant, but the eGFR didn’t change significantly. The 1-year eGFR was significantly lower in the hyperuricemic group (68.3±20.4 ml/min/1.73 m\(^2\)) than that in the normouricemic group (77.9±19.2 ml/min/1.73 m\(^2\)) (p = 0.000) [15]. Haririan et al found that RTRs with hyperuricemia during early post transplant period had significantly higher 1-year SCr, lower eGFR, and worse graft survival when compared with those with normal mean 6-month UA values [22].

The results of above studies in combination with our meta-analysis indicated that hyperuricemia may be an independent risk factor of graft dysfunction and may affect the life span of recipients of kidney transplantation.

Dose-response Association of Uric Acid Level with Graft Function

Min et al found that early-onset moderate-to-severe hyperuricemia (defined as UA=8.0 mg/dl) was found to be a significant risk factor for CAN (P=0.035) and a poorer graft survival (P=0.026) by multivariate analysis, but not mild hyperuricemia. In moderate-to-severe hyperuricemia group, the mean eGFRMDRD (Modification of Diet in Renal Disease) at the fourth post-transplant year were significantly lower than those at 1 year post-transplant (53.7±15.2 vs. 61.9±12.5). The impact of hyperuricemia on RTRs was dependent on the duration of exposure. Likewise, the detrimental effect of early-onset hyperuricemia on the graft function was dependent on UA-level and exposure time. After control of the baseline graft function by analysis of only recipients with a good graft function at 1 year post-transplantation (eGFR > 60 ml/min), moderate-to-severe early-onset hyperuricemia was also a marker of long-term graft dysfunction and failure [24]. Haririan et al found that higher UA level had significant higher risk of graft loss compared to lower UA level. Each 1 mg/dl, increase of UA level was associated with a 15% increase on average in the risk of graft loss during the study period and seemed to be associated with increased risk of death [26]. These two studies suggested that both higher UA-level and longer duration of exposure have severe impacts on graft function.

Advantages and Limitations

This meta-analysis has some advantages. First, the samples of included cohort studies came from Korea, China, Canada, Poland, Saudi Arabia, Turkey, USA and German that would have a good representative of race. Second, the effect of Hyperuricemia on renal function is consistent regardless of whether other confounding factors were adjusted or not. Third, the included studies have moderate to high quality and good internal validity.

Limitations of this study should be noted. First, the included studies had potential risk of bias due to differences in complete reporting of follow-up and judgment of outcomes. Second, although included study adjusted confounding factors relevant to renal function more or less, the number and types of adjusted factors were different. There are maybe residual confounding factors which have effects on outcomes. However, the pooled estimates found that no matter confounding factors adjusted or unadjusted, no matter how many confounding factors were adjusted, the conclusion that hyperuricemia is a risk factor of graft dysfunction and poor prognosis is consistent. Third, as the sample

| Study or Subgroup       | Odds Ratio  M-H, Fixed, 95% CI | Odds Ratio M-H, Fixed, 95% CI |
|-------------------------|-------------------------------|-------------------------------|
| Experimental Events     | Total                         | Weight                        | Total events |
| Chung2011                | 16                            | 148                           | 8            | 202 | 19.5% | 2.94 [1.22, 7.07] |
| Gerhardt1999             | 25                            | 80                            | 45           | 268 | 45.9% | 2.25 [1.27, 3.99] |
| Haririan2010             | 18                            | 45                            | 42           | 167 | 34.6% | 1.98 [0.99, 3.96] |
| Total (95% CI)           | 273                           | 637                           | 100.0%       | 95  |

Heterogeneity: Chi² = 0.48, df = 2 (P = 0.79); I² = 0%
Test for overall effect: Z = 4.15 (P < 0.0001)

Figure 5. Unadjusted odds ratio (OR) of hyperuricemia with graft loss.
doi:10.1371/journal.pone.0039457.g005
size of this meta-analysis was small, we can’t get the definitive conclusions. Fourth, our review only included studies which have been published in English or Chinese and did not search grey literature, publication bias may exist. We could not assess the publication bias precisely due to the limited number of included studies for each outcome (<10).

Conclusions and Implications for Clinical Practice and Research

Our systematic review shows that hyperuricemia has effects on eGFR and SCr of RTRs and hyperuricemia may be an independent risk factor of CAN and graft loss. Because this review is based on observational studies, the number of included studies and the sample size are limited and uric acid lowering drugs have potential bad effects on kidney function, the application of uric acid lowering drugs for RTRs with hyperuricemia is not yet routinely recommended. Future cohort studies need pay more attention to the representative of study people, the comparable baselines of different groups, the adjustment of confounding factors, long-term follow-up and assessment of outcomes. High quality clinical trials are needed to verify whether reducing the serum uric acid level can delay the kidney dysfunction after kidney transplantation, the process of chronic allograft nephropathy and the death of RTRs, and to provide basis for the reasonable application of uric acid lowering drugs.

Author Contributions

Conceived and designed the experiments: YH JL. Performed the experiments: YH YLL. Analyzed the data: YH LW. Wrote the paper: YH HH WMY JL.

References

1. Hashmi S, Poommipanit N, Kalwaji J, Bunnarapradit S (2007) Overview of renal transplantation. Minerva Medica 98: 713–729.
2. Karthikeyan V, Karpinski J, Nair RC, Knoll G (2004) The Burden of Chronic Kidney Disease in Renal Transplant Recipients. American Journal of Transplantation 4: 262–269.
3. Kato M, Hiuatome I, Tomikura Y, Kozan I, Kimuaga T, et al. (2003) Status of Endothelial Dependent Vasodilatation in Patients With Hyperuricemia. The American Journal of Cardiology 96: 1576–1578.
4. Khoda UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, et al. (2003) Hyperuricemia induces endothelial dysfunction. Kidney International 67: 1379–1382.
5. Gersch C, Pali PI, Kim KM, Angerhofer A, Johnson RJ, et al. (2008) Inactivation of nitric oxide by uric acid. Nucleosides, Nucleotides & Nucleic Acids 27: 967–978.
6. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, et al. (2003) Uric acid stimulates monocyte chemotactic protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41: 1267–1293.
7. Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, et al. (2003) Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. American Journal of Nephrology 25: 423–431.
8. Mazzali M, Kanellis J, Han L, Feng L, Xue Y, et al. (2002) Hyperuricemia induces a primary renal arteriole pathology in rats by a blood pressure-independent mechanism. American Journal of Physiology - Renal Physiology 282: F991–F997.
9. Kang DH, Park SK, Lee IK, Johnson RJ (2005) Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. Journal of the American Society of Nephrology 16: 3553–3562.
10. Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, et al. (2006) Uric acid and inflammatory markers. European Heart Journal 27: 1174–1181.
11. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, et al. (2009) Association between serum uric acid and development of type 2 diabetes. Diabetes care 32: 1737–1742.
12. Mazzali M (2005) Uric acid and transplantation. [Review] [66 refs]. Seminars in Inflammatory Bowel Disease 11: 3553–3562.
13. Yu-lin L, Ling W, Jing L, Yan H, Wen-ming Y (2011) The correlation between uric acid and the incidence and prognosis of kidney diseases: a systematic review and meta-analysis of cohort studies. CHINESE JOURNAL OF INTERNAL MEDICINE 50: 555–561.
14. Shi YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. American Journal of Kidney Diseases 47: 51–59.
15. Chung BH, Kang SH, Hwang HS, Choi BS, Park CW, et al. (2011) Clinical significance of early-onset hyperuricemia in renal transplant recipients. Nephron - Clinical Practice 117: c276–c283.
16. Gerhardt U, Huttunen MG, Hohage H (1999) Influence of hyperglycemia and hyperuricemia on long-term transplant survival in kidney transplant recipients. Clinical Transplantation 13: 375–379.
17. Zou GM, Soi WG, Yan Q, Che WT, Chen HZ, et al. (2010) Influence of hyperuricemia on long-term renal allograft function after renal transplantation* is it a factor of chronic renal allograft dysfunction? Journal of Clinical Reconstructive Tissue Engineering Research 14: 923–927.
18. Abdelrahman M, Rafa A, Ghacha R, Youmibbi JT, Qasuyan T, et al. (2002) Hyperuricemia and gout in transplant recipients. Renal Failure 24: 361–367.
19. Akalin E, Ganeshan SV, Winston J, Muntner P (2008) Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation 86: 652–658.
20. Akpul A, Bilge A, Ibis A, Odemir FN, Arar Z, et al. (2007) Is uric acid a predictive factor for graft dysfunction in renal transplant recipients? Transplantation Proceedings 39: 1023–1026.
21. Bandhulkava F, Huang M, Zaltman JS, Nash MM, Prasad GVR (2009) Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. American Journal of Cardiology 103: 867–871.
22. Haririan A, Noegueria JM, Zandi-Nejad K, Aiyer R, Hurley H, et al. (2010) The independent association between serum uric acid and graft outcomes after kidney transplantation. Transplantation 89: 573–579.
23. Karbowska A, Boratynska M, Kusztal M, Klinger M (2009) Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients. Transplantation Proceedings 41: 3052–3055.
24. Min SI, Yun JJ, Kang JM, Park YJ, Min SK, et al. (2009) Moderate-to-severe early-onset hyperuricemia: a prognostic marker of long-term kidney transplant outcome. Nephrology Dialysis Transplantation 24: 2584–2590.
25. Kim KM, Kim SS, Han DJ, Yang WS, Park JS, et al. (2010) Hyperuricemia in kidney transplant recipients with intact graft function. Transplantation Proceedings 42: 3562–3567.
26. Haririan A, Metcribeddy M, Cangro C, Noegueria JM, Rasetto F, et al. (2011) Association of serum uric acid with graft survival after kidney transplantation: a time-varying analysis. American Journal of Transplantation 11: 1943–1950.
27. Corry BD, Edlam P, Yama moto K, Nyby MD, Makino H, et al. (2006) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. Journal of Hypertension 26: 269-275 210.1097/HJH.0b013e3280172d4efef.
28. Feig DI, Kang DH, Johnson RJ (2008) Medical progress: Uric acid and cardiovascular risk. New England Journal of Medicine 359: 1011–1021.
29. Gaocecea M, de Vinuesa SG, Verdallés U, Ruiz-Caro C, Ampeust J, et al. (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clinical Journal of The American Society of Nephrology: CJASN 5: 1388–1393.
30. Flury W, Ruch HR, Muntandon A (1967) [The treatment of hyperuricemia after kidney transplantation]. [German]. Schweizische Medizinische Wochen-schrift: Journal Suisse de Medecine.
31. Navacua RA, Gomez E, Rodriguez M, Laurres AS, Balarj J, et al. (2002) Safety of the allopurinol/mycophenolate mofetil combination in the treatment of hyperuricemia of kidney transplant recipients. Nephron 91: 173–174.
32. Meier-Kriesche H-U, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H (2009) Uric acid levels have no significant effect on renal function in adult renal transplant recipients: evidence from the symphony study. Clinical Journal of The American Society of Nephrology: CJASN 4: 1653–1660.